The global Targeted Therapeutics market gathered revenue around USD 67.9 Billion in 2020 and market is set to grow USD 80 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 1.6% during the prediction period 2021 to 2027.
Report Coverage
| Report Scope | Details |
| Market Size | USD 80 Billion by 2027 |
| Growth Rate | CAGR of 1.6% From 2021 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2021 to 2027 |
| Historic Data | 2017 to 2020 |
| Report coverage | Growth Factors, Revenue Status, Competitive Landscape, and Future Trends |
| Segments Covered | Type, Application, Distribution Channel and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer, Inc. In |
Growth Factors:
Targeted therapies are drugs or other substances that block the growth of unwanted cells and pathogens by interfering with specific molecules ("molecular targets") involved in the growth, progression, and spread of disease. Targeted therapies are sometimes called molecularly targeted drugs, molecularly targeted therapies, precision medicines, etc. The emerging field of target therapeutics offers varied potential treatments. Targeted therapies offer the possibility of finding a cure for diseases with significant unmet needs, including orphan diseases and diseases having a high burden globally. Targeted therapy is widely used in the treatment of different forms of cancer such as renal, breast, lung, colorectal, and leukemia, and other diseases such as multiple sclerosis and wet age-related macular degeneration. The global targeted therapeutics market is driven by rise in prevalence of cancer across the globe, increase in global geriatric population, and surge in product approvals.
North America dominated the global targeted therapeutics market in 2020, followed by Europe, and the trend is anticipated to continue during the forecast period. North America’s dominance can be ascribed to high prevalence and increase in incidence rates of cancer, well-established healthcare industry, and rise in adoption of targeted therapeutics monoclonal antibodies in the region.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Targeted Therapeutics market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Targeted Therapeutics market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Targeted Therapeutics market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Targeted Therapeutics Market: Prominent Regions
In terms of region, the global targeted therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global targeted therapeutics market in 2020, followed by Europe. The U.S. dominated the targeted therapeutics market in North America in 2020, due to the presence of key players, adoption of targeted therapeutics monoclonal antibodies, and adequate reimbursement policies. This, in turn, is expected to boost the market in the region. The targeted therapeutics market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2027. The growth of the market in the region can be attributed to the adoption of new targeted therapeutic drugs, increase in awareness about various oncological disorders, rise in healthcare expenditure, and high penetration of research activities across the region.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Targeted Therapeutics Market are: Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer, Inc. In
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Global Targeted Therapeutics Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Targeted Therapeutics Market, By Type
7.1. Targeted Therapeutics Market, by Type, 2021-2027
7.1.1. Monoclonal Antibodies
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Small Molecule
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Targeted Therapeutics Market, By Application
8.1. Targeted Therapeutics Market, by Application, 2021-2027
8.1.1. Breast Cancer
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Colorectal Cancer
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Leukemia
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Lung Cancer
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Lymphoma
8.1.5.1. Market Revenue and Forecast (2016-2027)
8.1.6. Multiple Sclerosis
8.1.6.1. Market Revenue and Forecast (2016-2027)
8.1.7. Renal Cancer
8.1.7.1. Market Revenue and Forecast (2016-2027)
8.1.8. Wet Age-related Macular Degeneration
8.1.8.1. Market Revenue and Forecast (2016-2027)
8.1.9. Others
8.1.9.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Targeted Therapeutics Market, By Distribution Channel
9.1. Targeted Therapeutics Market, by Distribution Channel, 2021-2027
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Targeted Therapeutics Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
Chapter 11. Company Profiles
11.1. Amgen, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol-Myers Squibb Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Bayer AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Bayer AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Pfizer, Inc. In
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers